Broad range and great potential
The LAMELLASOME platform delivers nucleic acids to a diverse range of cells, offering the opportunity to realise the potential on many active-agent nucleic acids (e.g. mRNAs, siRNAs, DNA, miRs, plasmids etc) and revolutionise the treatment of many diseases. Lamellar has shown in vitro nucleic acid delivery to macrophages, human pulmonary fibroblasts and human dendritic cells and in vivo delivery to pulmonary cells.
Safe, effective and functional
The nature of the delivery represents a considerable advance in safe and effective transfection with all transfected cells types demonstrating very high viability, maintenance of phenotype and high transfection rates. In addition, Lamellar has demonstrated clear target downregulation by the transfected nucleic acid. This technology is novel and does not utilise viral vectors or cationic or divalent ion-associated liposomes.
Standard processing & customizable formulation
LAMELLASOME formulation uses standard scalable processes and conventional materials. The Company also has the know-how to customise and optimise the technology to deliver nucleic acids across the entire spectrum i.e. from microRNAs to plasmids. Lamellar is keen to engage with companies who have nucleic acids in development to demonstrate the ability of LAMELLASOME to deliver effectively.
As a proof of concept of the platform, Lamellar has taken two LAMELLASOME nucleic acid products and is advancing them through preclinical efficacy testing. These products target Idiopathic Pulmonary Fibrosis (LAMELLASOME IPF-NA) and Cystic Fibrosis (LAMELLASOME CF-NA) which are Orphan Drug Designated conditions with high unmet clinical need.
LAMELLASOME products have an excellent safety profile as demonstrated in GLP non-clinical safety and toxicity testing, and in two clinical studies.
Lamellar is currently looking for opportunities to advance these products through out-licensing or joint development agreements.